Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Sales 45,811,000 44,351,000 37,417,000 26,617,000 24,384,000
Sales Growth +3.29% +18.53% +40.58% +9.16% +10.38%
Net Income 5,955,000 3,288,000 112,000 3,196,000 1,335,000
Net Income Growth +81.11% +2,835.71% -96.50% +139.40% -38.05%
(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Total Assets 101,119,000 96,483,000 105,363,000 66,729,000 61,377,000
Total Assets Growth +4.81% -8.43% +57.90% +8.72% +1.20%
Total Liabilities 61,953,000 59,425,000 66,076,000 51,091,000 46,781,000
Total Liabilities Growth +4.25% -10.07% +29.33% +9.21% +0.37%
(Values in U.S. Thousands) Dec, 2023 Dec, 2022 Dec, 2021 Dec, 2020 Dec, 2019
Operating Cash Flow 10,345,000 9,808,000 5,963,000 4,799,000 2,969,000
Operating Cash Flow Growth +5.48% +64.48% +24.26% +61.64% +13.41%
Net Cash Flow -346,000 -55,000 -1,508,000 2,323,000 552,000
Change in Net Cash Flow -529.09% +96.35% -164.92% +320.83% -63.18%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar